News and Trends 25 Aug 2022Zelluna Immunotherapy announces investment from Takeda Ventures, Inc. Zelluna Immunotherapy, a company focused on allogenic T-cell Receptor Natural Killer (TCR-NK) cells to treat cancer has today (August 25)… August 25, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email